Neoplasms

Urinary Tract, Sexual Organs, and Pregnancy Conditions

All Conditions

Prostatic Neoplasms

Genital Neoplasms, Male

Urogenital Neoplasms

Genital Diseases

Genital Diseases, Male

Urogenital Diseases

Prostatic Diseases

Male Urogenital Diseases

Anti-Infective Agents

All Drugs and Chemicals

Benzimidazole

3-hydroxy-17-(1H-benzimidazole-1-yl)androsta-5,16-diene

Enzyme Inhibitors

TOK-001

3 capsules (325 mg each), once per day with supplement

6 capsules (325 mg each), split dose (3 capsules with breakfast, 3 capsules with dinner)

8 capsules (325 mg each), split dose (4 capsules with breakfast, 4 capsules with dinner)

R. B. Montgomery, MD

M. E. Taplin, MD

The purpose of this study is to determine whether TOK-001 is safe and shows biological effect in the treatment of castration resistant prostate cancer (CRPC).

ARMOR1: Study of TOK-001 to Treat Castration Resistant Prostate Cancer

ARMOR1: Phase 1, Open Label, Dose Escalation Trial of TOK-001 for the Treatment of Chemotherapy Naive Castration Resistant Prostate Cancer

Safety will be assessed by incidence of AEs and change from baseline in the following additional safety parameters: clinical laboratory assessments, physical examination, vital signs, and 12 lead electrocardiograms (ECGs)

Efficacy will be assessed by evaluation of change in PSA level, changes from baseline in CT/MRI and bone scans, response rate RECIST criteria and additional special laboratories

LTN PHARMACEUTICALS, INC.

Rare Diseases

Kennedy Disease

Androgens

Galeterone

160 mg enzalutamide capsules once daily PO

Enzalutamide

The purpose of this study is to compare galeterone to enzalutamide in men expressing androgen receptor spice variant-7 mRNA (AR-V7) in metastatic (M1) castrate resistant prostate cancer (CRPC).

A Study of Galeterone Compared to Enzalutamide In Men Expressing Androgen Receptor Splice Variant-7 mRNA (AR-V7) Metastatic CRPC

ARMOR3-SV: A Phase 3, Randomized, Open Label, Multi-Center, Controlled Study of Galeterone Compared to Enzalutamide in Men Expressing Androgen Receptor Splice Variant-7 mRNA (AR-V7) Metastatic (M1) Castrate Resistant Prostate Cancer (CRPC)

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization	Link
ARMOR1: Study of TOK-001 to Treat Castration Resistant Prostate Cancer	NCT00959959	Prostate Cancer	TOK-001 TOK-001 TOK-001 TOK-001 TOK-001 TOK-001 TOK-001 TOK-001	18 Years -	LTN PHARMACEUTICALS, INC.
A Study of Galeterone Compared to Enzalutamide In Men Expressing Androgen Receptor Splice Variant-7 mRNA (AR-V7) Metastatic CRPC	NCT02438007	Prostate Cancer	Galeterone Enzalutamide	18 Years -	LTN PHARMACEUTICALS, INC.

Spots Global Cancer Trial Database for galeterone

Every month we try and update this database with for galeterone cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

Spots Global Cancer Trial Database for galeterone

Every month we try and update this database with for galeterone cancer trials from around the world to help patients and their families find trials that might be right for them. We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

Every month we try and update this database with for galeterone cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.